NuCana plc (NCNA)

NCM – Real vaqt narxi. Valyuta: USD

1.86

-0.11 (-5.58%)

Yopilishda: May 12, 2026, 4:00 PM EDT

1.90

+0.04 (2.15%)

Bozor oldidan: May 13, 2026, 4:45 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

NuCana plc (NCNA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NuCana plc (NCNA)

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

NuCana Announces ADS Ratio Change

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Videolar

No Data

Press-relizlar

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Search stocks

NuCana plc (NCNA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NuCana plc (NCNA)

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

NuCana Announces ADS Ratio Change

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Videolar

No Data

Press-relizlar

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update